Business Wire

“Travel and tourism builds diversified and resilient economies”: Saudi Arabia Minister of Tourism, His Excellency Ahmed Al-Khateeb, tells World Economic Forum Annual Meeting in Davos

24.1.2025 21:59:00 EET | Business Wire | Press release

Share

The Travel and Tourism sector’s essential contribution to shaping the global landscape was underscored at the World Economic Forum (WEF) Annual Meeting in Davos this week with His Excellency Ahmed A. Al-Khateeb, Saudi Arabia Minister of Tourism, urging world leaders to provide the industry with the focus and collaborative solutions it deserves.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250124536028/en/

Saudi Minister of Tourism, His Excellency Ahmed A. Al-Khateeb put travel and tourism on the global agenda at the World Economic Forum Annual Meeting in Davos, Switzerland, this week. (Photo: AETOSWire)

Saudi Arabia welcomed nearly 30 million international visitors in 2024 and contributed almost 5% to the Kingdom’s GDP. In dedicated WEF sessions on travel and tourism, His Excellency, who attended Davos as part of the official Saudi Arabia WEF Delegation, highlighted the Kingdom’s unprecedented growth rates. He stressed the critical role that tourism has in building diversified and resilient economies, emphasizing that when Saudi Vision 2030 unlocked the travel and tourism sector, the Kingdom began building a holistic tourism experience based on international collaboration, best practices, and sustainable development.

As the WEF Annual Meeting concluded, His Excellency noted that the world was watching the remarkable resurgence of tourism, with the industry now fully recovered to pre-pandemic levels with 1.4 billion international arrivals in 2024.

“The world is counting on us to build a vibrant tourism ecosystem that meets growing demand while safeguarding our planet and quality of life. Tourism is more than an industry - it is a transformative force. We need to foster collective action to balance economic growth in the industry with social and environmental responsibility and ensuring the sector's resilience,” His Excellency said.

Throughout the forum, His Excellency led discussions as a key voice on official WEF panels including "Travel and Tourism’s Role in Building Trust” and "The Way We Will Travel”, focused on mobilizing diversified sector growth and enhancing global collaboration to propel the travel and tourism sector to keep up with growing demand, as well as a high-level session at Saudi House that explored “Scaling Sustainable Tourism: Connecting People and Places.”

He shared the stage with distinguished leaders, including Albania Prime Minister Edi Rama, European Commissioner for Transport and Tourism Apostolos Tzitzikostas, Switzerland Tourism CEO Martin Nydegger and Trip.com CEO Jane Sun who all shared His Excellency’s sentiment on the need for further global collaboration.

In alignment with Saudi Arabia’s forward-thinking tourism strategy, the Ministry launched a new investment guide, the "Hospitality Investor White Paper" during the WEF Annual Meeting. This initiative supports Vision 2030's ambitious targets, aiming to attract more than SAR 40 billion (USD 11 billion) in private investments, contribute SAR 16 billion (USD 4 billion) to the GDP, and create 1.6 million jobs by 2030.

Minister Al-Khateeb also contributed expert insights to the WEF’s "The Future of Travel and Tourism: Embracing Sustainable and Inclusive Growth” briefing paper highlighting the growing demand for sustainable travel and the importance of cross-sector collaboration and the need to ensure local communities globally benefit from the resulting growth.

As the WEF Annual Meeting concludes, Minister Al-Khateeb's participation underscores Saudi Arabia's transformative role in reshaping the global tourism landscape, reinforcing the Kingdom's vision to establish itself as a leading hub for sustainable travel.

*Source: AETOSWire

View source version on businesswire.com: https://www.businesswire.com/news/home/20250124536028/en/

Contacts

Media Contacts:

Najla AlKhalifa, Ministry of Tourism Senior Communications Advisor, at
MTDavos2025@apcoworldwide.com

Kelsey Glover at kglover@apcoworldwide.com or +1 513 319 6103

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye